Osborne Partners Capital Management’s AbbVie ABBV Stock Holding History

Osborne Partners Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-11,479	Closed	-$2.5M	–	204
2026 Q1	$2.5M	Sell	11,479 -216	-2%	-$47.9K	0.13%	119
2025 Q4	$2.67M	Sell	11,695 -616	-5%	-$140K	0.14%	117
2025 Q3	$2.85M	Buy	12,311 +700	+6%	+$143K	0.14%	116
2025 Q2	$2.16M	Sell	11,611 -1,272	-10%	-$236K	0.11%	128
2025 Q1	$2.7M	Buy	12,883 +42	+0.3%	+$8.16K	0.16%	118
2024 Q4	$2.28M	Buy	12,841 +58	+0.5%	+$10.7K	0.13%	122
2024 Q3	$2.52M	Buy	12,783 +53	+0.4%	+$9.89K	0.14%	118
2024 Q2	$2.18M	Hold	12,730	–	–	0.13%	120
2024 Q1	$2.32M	Sell	12,730 -118	-0.9%	-$20.3K	0.14%	115
2023 Q4	$1.99M	Hold	12,848	–	–	0.13%	118
2023 Q3	$1.92M	Sell	12,848 -350	-3%	-$51.4K	0.14%	113
2023 Q2	$1.78M	Buy	13,198 +277	+2%	+$40.6K	0.13%	119
2023 Q1	$2.06M	Sell	12,921 -34	-0.3%	-$5.2K	0.15%	115
2022 Q4	$2.09M	Sell	12,955 -83	-0.6%	-$12.7K	0.16%	115
2022 Q3	$1.75M	Sell	13,038 -404	-3%	-$58K	0.15%	119
2022 Q2	$2.06M	Buy	13,442 +9,773	+266%	+$1.49M	0.16%	117
2022 Q1	$595K	Sell	3,669 -117	-3%	-$17K	0.04%	137
2021 Q4	$513K	Sell	3,786 -1,310	-26%	-$155K	0.04%	148
2021 Q3	$550K	Sell	5,096 -253	-5%	-$28.9K	0.04%	140
2021 Q2	$603K	Buy	5,349 +552	+12%	+$62.2K	0.05%	139
2021 Q1	$519K	Sell	4,797 -9,927	-67%	-$1.06M	0.05%	142
2020 Q4	$1.58M	Buy	14,724 +3,666	+33%	+$352K	0.19%	102
2020 Q3	$969K	Sell	11,058 -148	-1%	-$13.9K	0.2%	89
2020 Q2	$1.1M	Buy	11,206 +10	+0.1%	+$880	0.24%	83
2020 Q1	$853K	Hold	11,196	–	–	0.22%	84
2019 Q4	$991K	Sell	11,196 -17,800	-61%	-$1.48M	0.2%	82
2019 Q3	$2.2M	Sell	28,996 -202	-0.7%	-$13.8K	0.44%	68
2019 Q2	$2.12M	Sell	29,198 -2,162	-7%	-$170K	0.41%	74
2019 Q1	$2.53M	Sell	31,360 -11,688	-27%	-$956K	0.49%	65
2018 Q4	$3.97M	Sell	43,048 -1,080	-2%	-$95K	0.59%	57
2018 Q3	$4.17M	Sell	44,128 -2,662	-6%	-$252K	0.53%	65
2018 Q2	$4.33M	Sell	46,790 -544	-1%	-$53.1K	0.59%	63
2018 Q1	$4.48M	Sell	47,334 -755	-2%	-$82.9K	0.62%	57
2017 Q4	$4.65M	Sell	48,089 -672	-1%	-$63.3K	0.62%	60
2017 Q3	$4.33M	Sell	48,761 -1,670	-3%	-$127K	0.59%	61
2017 Q2	$3.66M	Sell	50,431 -555	-1%	-$37.3K	0.52%	65
2017 Q1	$3.32M	Sell	50,986 -1,416	-3%	-$89K	0.48%	73
2016 Q4	$3.28M	Buy	52,402 +1,476	+3%	+$90.1K	0.48%	70
2016 Q3	$3.21M	Sell	50,926 -1,540	-3%	-$99.7K	0.48%	70
2016 Q2	$3.25M	Buy	52,466 +2,711	+5%	+$165K	0.48%	67
2016 Q1	$2.84M	Sell	49,755 -2,367	-5%	-$132K	0.42%	74
2015 Q4	$3.09M	Sell	52,122 -350	-0.7%	-$20.2K	0.45%	73
2015 Q3	$2.85M	Sell	52,472 -640	-1%	-$41.7K	0.42%	70
2015 Q2	$3.57M	Sell	53,112 -689	-1%	-$45K	0.48%	66
2015 Q1	$3.15M	Sell	53,801 -102	-0.2%	-$6.16K	0.41%	71
2014 Q4	$3.53M	Sell	53,903 -760	-1%	-$47.9K	0.43%	64
2014 Q3	$3.16M	Sell	54,663 -4,139	-7%	-$230K	0.41%	63
2014 Q2	$3.32M	Sell	58,802 -3,217	-5%	-$169K	0.43%	65
2014 Q1	$3.19M	Buy	62,019 +2,524	+4%	+$128K	0.42%	64
2013 Q4	$3.14M	Buy	59,495 +4,965	+9%	+$244K	0.41%	64
2013 Q3	$2.44M	Buy	54,530 +9,400	+21%	+$417K	0.34%	71
2013 Q2	$1.87M	Buy	+45,130	New	+$1.97M	0.27%	82

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Osborne Partners Capital Management's ABBV Position: Q2 2026 in Review

Osborne Partners Capital Management sold out of AbbVie (ABBV) in Q2 2026, closing a stake of 11,479 shares — an estimated $2.5M sold.

Osborne Partners Capital Management first reported a position in ABBV in Q2 2013 and held it in 52 quarters. The position peaked at $4.65M in Q4 2017. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Osborne Partners Capital Management reported no remaining AbbVie position as of Q2 2026 after selling out during the quarter.
Osborne Partners Capital Management sold 11,479 AbbVie shares in Q2 2026, an estimated $2.5M.
Osborne Partners Capital Management first reported a position in AbbVie in Q2 2013 and held it in 52 quarters.
Osborne Partners Capital Management's AbbVie position peaked at $4.65M in Q4 2017.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Osborne Partners Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.